Hikari Power’s Celldex Therapeutics CLDX Stock Holding History

Hikari Power’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,333	Closed	-$181K	–	97
2017 Q1	$181K	Buy	+3,333	New	+$174K	0.03%	65

Other funds holding CLDX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Hikari Power's CLDX Position: Q2 2017 in Review

Hikari Power sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 3,333 shares — an estimated $181K sold.

Hikari Power first reported a position in CLDX in Q1 2017 and held it in 1 quarter. The position peaked at $181K in Q1 2017. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

Hikari Power reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
Hikari Power sold 3,333 Celldex Therapeutics shares in Q2 2017, an estimated $181K.
Hikari Power first reported a position in Celldex Therapeutics in Q1 2017 and held it in 1 quarter.
Hikari Power's Celldex Therapeutics position peaked at $181K in Q1 2017.
130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Hikari Power's 13F filing for Q2 2017, filed 9 Aug 2017.